Allogeneic hematopoietic stem cell transplantation
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a cellular therapy in which hematopoietic stem cells from an HLA-compatible donor are infused into a recipient after conditioning therapy.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a cellular therapy in which hematopoietic stem cells from an HLA-compatible donor are infused into a recipient after conditioning therapy. The donor cells repopulate the hematopoietic and immune systems through engraftment and may provide an immune-mediated graft-versus-leukemia or graft-versus-tumor effect. This approach is used in selected hematologic malignancies and disorders, including acute myeloid leukemia, myelodysplastic syndrome, B-cell acute lymphoblastic leukemia, extranodal NK/T-cell lymphoma, and high-risk hemophagocytic lymphohistiocytosis; it may also be considered for severe sickle cell disease and selected inflammatory or clonal disorders such as VEXAS syndrome.
The procedure is associated with substantial risks, including relapse, non-relapse mortality, infections such as cytomegalovirus and adenovirus, delayed immune reconstitution, and acute or chronic graft-versus-host disease, in which donor immune cells attack recipient tissues. Clinical assessment therefore includes disease response and measurable residual disease, engraftment, relapse-free and overall survival, toxicity, fatigue, and quality of life. Recent work has examined education and supportive care after transplantation, molecular MRD clearance and long-term survival in KMT2A-altered acute myeloid leukemia, post-transplant blood rheology in sickle cell disease, and outcomes in pediatric and disease-specific transplant populations.
Where the papers sit
8 papers from the last 6 months study allogeneic hematopoietic stem cell transplantation directly · updated from PubMed 16 Nov 2026
Study type 0 clinical trials · 6 observational · 2 human data
Themes one subject · 1 paradigm shift
Those 8 are all about one subject.
-
Allogeneic Transplant Care
Clinical care around allogeneic transplantation remains broad, spanning education, survival, quality of life, infections, and disease-specific outcomes. Recurring concerns include graft-versus-host disease, adenovirus infection, fatigue, molecular MRD clearance, and post-transplant blood rheology. Studies also examine transplantation for VEXAS syndrome, extranodal NK/T-cell lymphoma, hemophagocytic lymphohistiocytosis, and sickle cell disease. No single management direction or consensus emerges across these topics.
Allogeneic transplantation is not interchangeable with nontransplant therapy when deep biological correction matters
The KMT2A-altered acute myeloid leukemia cohort and the sickle cell disease blood-rheology comparison both challenge the assumption that comparable clinical treatment categories imply comparable biological correction. In KMT2A-altered AML, nontransplant regimens produced similar survival, whereas allogeneic transplantation was associated with sustained molecular MRD negativity in 74.6% versus 14.4% without transplantation; in sickle cell disease, transplantation from donors with sickle cell trait produced superior rheologic parameters compared with autologous gene therapy and optimally responsive hydroxyurea. Together, these findings give allogeneic transplantation a distinct disease-eradicating or physiologic-normalizing effect that cannot be inferred from conventional survival, symptom, or clinical-response comparisons alone 43016283Nov 42448317Jul.
Papers
The 8 papers from the last 6 months that study allogeneic hematopoietic stem cell transplantation directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Allogeneic Transplant Care (8)
- An education pathway for allogeneic transplant using the Listen, Establish, Adopt, Reinforce, Name, and Strengthen model: a quantitative study. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 14 Nov 2026 PMID 43033272
- Allogeneic hematopoietic stem cell transplantation is associated with improved long-term survival and molecular MRD clearance in KMT2A-altered AML. Annals of medicine · 12 Nov 2026 PMID 43016283
- Fatigue and quality of life in the early phase after allogeneic hematopoietic stem cell transplantation: dynamics and the impact of graft-versus-host disease. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 10 Oct 2026 PMID 42859258
- Early-onset VEXAS syndrome mimicking orbital cellulitis and successfully treated with allogeneic hematopoietic stem cell transplantation. Journal of hematopathology · 6 Oct 2026 PMID 42836952
- Incidence and Outcomes of Human Adenovirus Infection and Disease in a Multicenter Cohort of Pediatric Allogeneic Hematopoietic Cell Transplant Recipients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 20 Aug 2026 PMID 42619328
- Blood rheology after allogeneic hematopoietic stem cell transplantation or gene therapy in sickle cell disease. Blood advances · 14 Jul 2026 PMID 42448317
- Allogeneic HSCT may improve survival in advanced extranodal NK/T-cell lymphoma: a single-center retrospective study. Blood advances · 10 Jul 2026 PMID 42431626
- Retrospective study on allogeneic hematopoietic stem cell transplantation for the treatment of Hemophagocytic lymphohistiocytosis. Transplant immunology · 23 Jun 2026 PMID 42336251
By study type
Observational studies and case reports (6)
- Allogeneic hematopoietic stem cell transplantation is associated with improved long-term survival and molecular MRD clearance in KMT2A-altered AML. Annals of medicine · 12 Nov 2026 PMID 43016283
- Fatigue and quality of life in the early phase after allogeneic hematopoietic stem cell transplantation: dynamics and the impact of graft-versus-host disease. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 10 Oct 2026 PMID 42859258
- Early-onset VEXAS syndrome mimicking orbital cellulitis and successfully treated with allogeneic hematopoietic stem cell transplantation. Journal of hematopathology · 6 Oct 2026 PMID 42836952
- Incidence and Outcomes of Human Adenovirus Infection and Disease in a Multicenter Cohort of Pediatric Allogeneic Hematopoietic Cell Transplant Recipients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 20 Aug 2026 PMID 42619328
- Allogeneic HSCT may improve survival in advanced extranodal NK/T-cell lymphoma: a single-center retrospective study. Blood advances · 10 Jul 2026 PMID 42431626
- Retrospective study on allogeneic hematopoietic stem cell transplantation for the treatment of Hemophagocytic lymphohistiocytosis. Transplant immunology · 23 Jun 2026 PMID 42336251
Human data, design not indexed (2)
- An education pathway for allogeneic transplant using the Listen, Establish, Adopt, Reinforce, Name, and Strengthen model: a quantitative study. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 14 Nov 2026 PMID 43033272
- Blood rheology after allogeneic hematopoietic stem cell transplantation or gene therapy in sickle cell disease. Blood advances · 14 Jul 2026 PMID 42448317
Written from 8 PubMed abstracts, each one listed by PMID above. Published: 2026-11-16. Drafted by language models from published abstracts; not medical advice.